E-therapeutics Plc
ETXPF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -33.1% | -25.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 74.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,315.4% | -1,953.9% | -1,484.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -3,511.3% | -1,741.9% | -1,691.2% |
| EPS Diluted | -0.02 | -0.019 | -0.015 | -0.022 |
| % Growth | -5.2% | -24% | 30.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |